Redalpine is an investment firm whose portfolio includes companies such as 9fin.
Portfolio
7
companies
AUM
£1.0B
under management
9fin
9fin provides a data and analytics platform for debt capital markets.
Apoha
Apoha builds a behavioural data layer for molecular and material science.
Basecamp Research
A biotechnology company developing biological foundation models and cell therapies.
DaltonTx
DaltonTx develops adaptive AI platforms to accelerate drug discovery for pharmaceutical and biotech organisations.
Hypervision Surgical
Hypervision Surgical develops an advanced surgical imaging and data analytics platform.
Level Zero Health
Level Zero Health develops wearable technology for continuous hormone monitoring.
Aleksandra Laska
Partner
Daniel Dillinger
Investment Manager
Daniel brings venture capital investment experience from Redalpine, alongside board and advisory roles across multiple startups.
LinkedIn
Philip Kneis
Investor
Philip invests at Redalpine and holds board observer or director roles at several early stage companies. He previously held a leadership role at the University of Oxford.
LinkedIn
Marc Moesser
Investment Manager
Marc is a principal at Redalpine, where he holds investor and board roles across several companies following a PhD in machine learning from Oxford.
LinkedInThe financing values the biotechnology company at $800m and will support its in vivo cell therapy pipeline.
"We believe the future of medicine lies in reprogramming the body to repair itsel. We design the models and the medicines to teach it howf"
Singular led the funding round, with participation from Draper Associates and seed investors.
"Liquid State Intelligence took 15 years of science and 5 years of company-building to bring to life,"
The London fintech reached a valuation of $1.3bn with backing from HarbourVest and CPP Investments.
Redalpine led the Series A round to support team expansion and the rollout of new capabilities.
"Synthesized is tackling one of the most urgent and overlooked challenges in the age of AI: how to test, validate, and trust what we build. Their platform doesn’t just generate high-quality test data – it lays the foundation for a new class of autonomous QA agents that will transform how modern software is verified and shipped. We believe Synthesized can become the infrastructure layer for intelligent, automated quality assurance across regulated and mission-critical systems."
The seed round was backed by Redalpine, IQ Capital Partners, and Seedcamp.
"AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities. DaltonTx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability."
